Recent advances in managing human papillomavirus-positive oropharyngeal tumors

Giulio Cantu*, Stefano Riccio, Sarah Colombo, Madia Pompilio and Paolo Formillo

Address: National Cancer Institute of Milan, Via Venezian, 1, 20133 Milano, Italy

* Corresponding author: Giulio Cantu (giulio.cantu@istitutotumori.mi.it)

F1000 Medicine Reports 2010, **2**:17 (doi:10.3410/M2-17)

The electronic version of this article is the complete one and can be found at: <http://f1000.com/reports/medicine/content/2/17>

Abstract

Human papillomavirus (HPV) is detected in a subset of patients with head and neck squamous cell carcinoma, most frequently in tumors in the Waldeyer's ring (palatine tonsil and base of tongue). Several studies suggest that patients with HPV-positive tumors have better survival with either concurrent chemoradiation therapy or surgery followed by radiation compared with HPV-negative patients. However, some possible confounding clinicopathologic variables may challenge the validity of this statement, for example, some authors used the TNM (tumor, node, metastasis) grouping stage while others used the primary tumor (T stage), and other studies have demonstrated that tumors with advanced T stage were less likely to be infected with HPV. A large clinical trial with stratification of patients according to all known tumor prognostic factors is crucial to solve the question.

Introduction and context

It has been well established that alcohol use or cigarette smoking or both are the most significant risk factors for the development of head and neck squamous cell carcinomas (HNSCCs). However, nearly every head and neck oncologist has come across patients, most of them young, with little or no tobacco or alcohol consumption (up to 20% in some cases) [1].

Sturgis and Cinciripini [2] demonstrated decreasing incidence rates for tobacco-associated oral, pharyngeal, and laryngeal cancers since the mid-1980s, and these rates trailed the declines in smoking prevalence by 10-15 years. On the other hand, oropharyngeal cancer is not demonstrating a similar decline [3]. Shiboski *et al.* [4] found a dramatic rise in the incidence rates of oropharyngeal cancer in adults younger than 45 years of age in the US (2% per year for base-of-tongue cancer and 4% per year for tonsil cancer). As far back as 1982, the presence of human papillomavirus (HPV) antigens in 36% of pathologic specimens of laryngeal cancers was demonstrated [5].

Since then, several hundred papers on this topic have been published. We made a query on PubMed using the key words 'HPV, head and neck cancer' and found 1410 papers.

Recent advances

HPV genomic DNA was detected in 26% of all HNSCCs [6], whereas approximately 50% of oropharyngeal cancers contained the HPV genome [7]. By contrast, in a multinational study, only 18% of oropharyngeal tumors were HPV⁺ [8], indicating that this proportion varies with geography and sexual behavior (history of performing oral sex and oral-anal contact) [9]. Some studies found that patients who had sexual intercourse at an early age and more than six oral sexual partners in their lifetime had a fivefold risk of having HPV in their tumor compared with patients with no oral sexual partners [10,11]. Also, a significant racial difference in HPV positivity was found in a clinical trial of induction chemotherapy followed by concurrent chemoradiation therapy between white patients (35%) and black patients (4%) [12].

Several studies demonstrated an improved prognosis for patients with HPV⁺ tumors versus patients with HPV⁻ tumors with (chemo)radiation treatment [7,13,14]. Other studies found the same results in both patients treated with radiation or surgery and radiation [15-18]. Haraf *et al.* [19], investigating the correlation between HPV infection and p53 mutation in HNSCCs, found that patients with p53 mutations had a history of heavier smoking in comparison with patients with HPV infection, who conversely had a more advanced stage at diagnosis. In a paper from our institution [20], we analyzed a homogenous group of surgically treated oropharyngeal cancers with or without postoperative radiotherapy according to commonly accepted pathologic risk factors. Patients were divided into three groups according to HPV, TP53 (tumor protein p53), and p16 status. Patients harboring high-risk HPV showed a significant improvement in terms of survival and occurrence of relapse and a lower incidence of smoking-related second primary tumors, independently of tumor stage and delivered treatment (surgery alone or surgery and postoperative radiotherapy), thus confirming that HPV⁺ tumors represent a distinct disease among oropharyngeal cancers. In contrast, p53 mutation and p16 status seemed to lack prognostic significance in the absence of HPV infection. Similar results are reported by Weinberger *et al.* [21].

Begum *et al.* [22] detected HPV-16 in 22 of 68 (32%) lymph node metastases in patients with HNSCC and found that all HPV-16⁺ lymph nodes were metastases from the oropharynx. Goldenberg *et al.* [23] found a correlation between patients with cystic lymph node metastases and the presence of HPV DNA. Almost all of these patients had a tumor in the palatine or lingual tonsil.

Implications for clinical practice

The quoted retrospective analyses must be interpreted with caution because of possible confounding data. For example, Schwartz *et al.* [17] analyzed HPV infection and survival in oral cancers, but 31.5% of their patients had an oropharyngeal tumor (tonsil and base of the tongue). Nevertheless, the association between HPV status and prognosis seems to be indisputable, with a better disease-specific survival for patients with HPV⁺ oropharyngeal cancers in comparison with HPV⁻ patients, whereas disease-specific survival was similar for HPV⁺ or HPV⁻ patients with nonoropharyngeal cancer [24]. Some authors even demonstrated a worse prognosis for HPV⁺ patients with laryngeal and hypopharyngeal carcinomas in comparison with HPV⁻ patients [25]. Hence, the matter seems to be restricted to oropharyngeal cancer, and the diagnosis of HPV positivity should enter as a

routine test for these patients. The most clinically useful test, *in situ* hybridization, is available in only a few centers which is unfortunate, even if p16 immunohistochemistry may serve as a reasonable surrogate [7].

Another possible bias in the interpretation of the results of some studies is due to the staging of the presented patients, as some authors used the AJCC-UICC (American Joint Cancer Committee/Union Internationale Contre le Cancer) stage grouping [12,15,18,20,24,26]. It is well known that in stage III there are T1-N1 and T3-N0 tumors, and in stage IVA there are T1-N2 and T4a-N0, and these are clearly different tumors. Looking to those papers reporting T stage, we may realize that although overall TNM (tumor, node, metastasis) stage does not differ by HPV status, HPV⁺ tumors are more likely than HPV⁻ tumors to have a lower T stage [16,27], whereas advanced T stage is a significant risk factor for recurrence and death, independently of HPV status [14]. Some historic papers on results of radiation therapy for oropharyngeal tumors demonstrated that vegetating tumors (T1-T2) are more curable than infiltrating tumors (T4) [28,29]. Shonka *et al.* [30] demonstrated that patients with p16⁺ oropharyngeal tumors are less likely to have a persistent viable tumor in neck lymph nodes after (chemo)radiotherapy and hypothesized that a post-treatment planned neck dissection may perhaps be avoided in p16⁺ patients.

In conclusion, several authors indicate that the impact of HPV status must be evaluated in prospective clinical trials and included as a stratification factor to avoid potential confusion. The current AJCC-UICC staging system for oropharyngeal cancer needs to be modified in order to better reflect different prognoses for patients with HPV⁺ or HPV⁻ tumors and those with vegetating or infiltrating tumors.

Abbreviations

AJCC-UICC, American Joint Cancer Committee/Union Internationale Contre le Cancer; HNSCC, head and neck squamous cell carcinomas; HPV, human papillomavirus.

Competing interests

The authors declare that they have no competing interests.

References

1. Gillespie MB, Rubinchik S, Hoel B, Sutkowski N: **Human papillomavirus and oropharyngeal cancer: what you need to know in 2009.** *Curr Treat Options Oncol* 2009. [Epub ahead of print].
2. Sturgis EM, Cinciripini PM: **Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?** *Cancer* 2007, **110**:1429-35.

3. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP: **Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database.** *Int J Cancer* 2005, **114**:806-16.
4. Shiboski CH, Schmidt BL, Jordan RC: **Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years.** *Cancer* 2005, **103**:1843-9.
5. Syrjänen K, Syrjänen S, Pyrhönen S: **Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas.** *ORL J Otorhinolaryngol Relat Spec* 1982, **44**:323-34.
6. Kreimer AR, Clifford GM, Boyle P, Franceschi S: **Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.** *Cancer Epidemiol Biomarkers Prev* 2005, **14**:467-75.
7. Fakhry C, Gillison ML: **Clinical implications of human papillomavirus in head and neck cancers.** *J Clin Oncol* 2006, **24**:2606-11.
8. Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernández L, Idris A, Sánchez MJ, Nieto A, Talamini R, Tavani A, Bosch FX, Reidel U, Snijders PJ, Meijer CJ, Viscidi R, Muñoz N, Franceschi S; IARC Multicenter Oral Cancer Study Group: **Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.** *J Natl Cancer Inst* 2003, **95**:1772-83.
9. Smith EM, Ritchie JM, Summersgill KF, Klusmann JP, Lee JH, Wang D, Haugen TH, Turek LP: **Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers.** *Int J Cancer* 2004, **108**:766-72.
10. Anaya-Saavedra G, Ramírez-Amador V, Irigoyen-Camacho ME, García-Cuellar CM, Guido-Jiménez M, Méndez-Martínez R, García-Carrancá A: **High association of human papillomavirus infection with oral cancer: a case-control study.** *Arch Med Res* 2008, **39**:189-97.
11. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R: **Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.** *J Natl Cancer Inst* 2008, **100**:407-20.
12. Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Campbell EV 3rd, Sarlis N, Lorch J, Cullen KJ: **Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.** *Cancer Prev Res (Phila Pa)* 2009, **2**:776-81.
13. Lindel K, Beer KT, Laissue J, Greiner RH, Aebbersold DM: **Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma.** *Cancer* 2001, **92**:805-13.
14. Sedaghat AR, Zhang Z, Begum S, Palermo R, Best S, Ulmer KM, Levine M, Zinreich E, Messing BP, Gold D, Wu AA, Niparko KJ, Kowalski J, Hirata RM, Saunders JR, Westra WH, Pai SI: **Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas.** *Laryngoscope* 2009, **119**:1542-9.
15. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klusmann JP, Turek LP, Haugen TH: **Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx.** *Int J Cancer* 2003, **104**:336-44.
16. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E: **Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival.** *Int J Cancer* 2000, **89**:300-4.
17. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM: **Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study.** *Otolaryngol Head Neck Surg* 2001, **125**:1-9.
18. Li W, Thompson CH, O'Brien CJ, McNeil EB, Scolyer RA, Cossart YE, Veness MJ, Walker DM, Morgan GJ, Rose BR: **Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil.** *Int J Cancer* 2003, **106**:553-8.
19. Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Vokes EE, Weichselbaum RR: **Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival.** *Clin Cancer Res* 1996, **2**:755-62.
20. Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantù G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, Pilotti S: **High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.** *J Clin Oncol* 2006, **24**:5630-6.
21. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A: **Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis.** *J Clin Oncol* 2006, **24**:736-47.
22. Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH: **Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin.** *Clin Cancer Res* 2003, **9**:6469-75.
23. Goldenberg D, Begum S, Westra WH, Khan Z, Sciubba J, Pai SI, Califano JA, Tufano RP, Koch WM: **Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon.** *Head Neck* 2008, **30**:898-903.
24. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D: **Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.** *J Natl Cancer Inst* 2000, **92**:709-20.
25. Clayman GL, Stewart MG, Weber RS, el-Naggar AK, Grimm EA: **Human papillomavirus in laryngeal and hypopharyngeal carcinomas. Relationship to survival.** *Arch Otolaryngol Head Neck Surg* 1994, **120**:743-8.
26. Jo S, Juhasz A, Zhang K, Ruel C, Loera S, Wilczynski SP, Yen Y, Liu X, Ellenhorn J, Lim D, Paz B, Somlo G, Vora N, Shibata S: **Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial.** *Anticancer Res* 2009, **29**:1467-74.
27. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML: **Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.** *J Natl Cancer Inst* 2008, **100**:261-9.

F1000 Factor 6.0 Must Read
Evaluated by Athanassios Argiris 03 Mar 2008

28. Lee WR, Mendenhall WM, Parsons JT, Million RR, Cassisi NJ, Stringer SP: **Carcinoma of the tonsillar region: a multivariate analysis of 243 patients treated with radical radiotherapy.** *Head Neck* 1993, **15**:283-8.
29. Brunin F, Mosseri V, Jaulerry C, Point D, Cosset JM, Rodriguez J: **Cancer of the base of the tongue: past and future.** *Head Neck* 1999, **21**:751-9.
30. Shonka DC Jr, Shoushtari AN, Thomas CY, Moskaluk C, Read PW, Reibel JF, Levine PA, Jameson MJ: **Predicting residual neck disease in patients with oropharyngeal squamous cell carcinoma treated with radiation therapy: utility of p16 status.** *Arch Otolaryngol Head Neck Surg* 2009, **135**:1126-32.